drugset / Trial / NCT00267592

Safety and Efficacy of Talampanel in Glioblastoma Multiforme

NCT00267592

Phase 2 Completed 72 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to estimate overall survival for adult patients with newly diagnosed glioblastoma multiforme treated with talampanel during radiation therapy with concurrent and adjuvant temozolomide. This study will also determine the toxicity and toxicity rate of talampanel for this therapeutic regimen.

Timeline

Start
2005-12
Primary completion
2008-09
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Talampanel Small molecule Oral
Background Temozolomide Small molecule 200 mg

Indications